GlassScriptPhysician profile
Roshan S Shah
NPI 1003304940
$5,276.94
in general payments reported to CMS, 2019-2025
13 companies · $4,391 in 2025
The $4,391 reported for 2025 was more than what 97% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $191 · 2022: $40.03 · 2023: $90.10 · 2024: $565 · 2025: $4,391.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $2,500 · Travel and Lodging: $1,433 · Food and Beverage: $1,114.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $2,500.00 |
| Travel and Lodging | $1,432.67 |
| Food and Beverage | $1,113.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $3,949.66 | 2025 | |
| Glaxosmithkline, LLC. | $374.06 | 2022-2025 | Arexvy, Nucala |
| Zimmer Biomet Holdings, INC. | $284.29 | 2021-2024 | Persona |
| Astrazeneca Pharmaceuticals LP | $260.20 | 2024-2025 | Fasenra, Airsupra, Breztri |
| Viatris Specialty LLC | $155.75 | 2025 | Yupelri |
| Genzyme Corporation | $66.13 | 2024 | |
| Insmed, INC. | $52.21 | 2025 | Brinsupri, Arikayce |
| United Therapeutics Corporation | $32.87 | 2025 | Tyvaso |
| Merck Sharp & Dohme LLC | $29.56 | 2025 | Winrevair |
| Verona Pharma, INC. | $19.84 | 2025 | Ohtuvayre |
| Abbvie INC. | $19.80 | 2023 | Teflaro |
| Philips North America LLC | $18.21 | 2021 | |
| Amgen INC. | $14.36 | 2025 | Tezspire |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roshan Shah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.